Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes

By LabMedica International staff writers
Posted on 24 Mar 2026

Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. More...

Breath-based diagnostics promise faster answers but typically rely on bulky instruments unavailable at most points of care. Detecting trace disease biomarkers in exhaled breath has therefore been challenging outside specialized labs. Researchers now report a portable sensor that captures and reads synthetic pneumonia biomarkers from breath within minutes.

At the Massachusetts Institute of Technology (MIT), engineers have developed a chip-scale breath sensor designed for rapid, point-of-care detection of pneumonia and other lung conditions. The system pairs inhalable nanoparticles carrying synthetic biomarkers with a surface engineered to trap and read those biomarkers after disease-specific cleavage. The team plans to incorporate the sensor into a handheld instrument for use in clinical or at-home settings.

The device, called PlasmoSniff, operates by leveraging plasmonics and Raman spectroscopy. Patients would inhale nanoparticles tagged with synthetic biomarkers that cleave only in the presence of disease-related enzymes, such as those associated with pneumonia. Cleaved biomarkers are exhaled and pass through a nanogap formed between a thin gold film and gold nanoparticles coated with a porous silica shell. Water-mediated hydrogen bonding within this 5-nanometer gap captures the target molecules, while plasmonic resonance amplifies their Raman scattering, enabling identification by their vibrational “fingerprints.”

For the study, researchers evaluated the sensor using samples of lung fluid from healthy mice spiked with pneumonia biomarkers previously developed by the team. The samples were evaporated to simulate exhaled breath, the sensor was mounted on the vial cap, and a Raman spectrometer measured scattered light as vapor passed through the device. The sensor quickly detected pneumonia biomarkers at extremely low, clinically relevant concentrations. Earlier work reported in 2020 showed these biomarkers appear in infected mice at about 10 parts per billion using mass spectrometry.

The study is published online in Nano Letters. Several characterization and fabrication steps were conducted at MIT.nano. The team notes the platform can detect diseases beyond pneumonia, as well as non-disease biomarkers, provided the target has a known vibrational fingerprint.

“Our next goal is to have a breath collection system, like a mask you can breathe into. A patient would first use something like an asthma inhaler to inhale the nanoparticles. They could then breathe through the mask sensor for five minutes. We could then integrate a handheld Raman spectrometer to detect whatever biomarker is breathed out, within minutes,” said Aditya Garg, a postdoc in MIT’s Department of Mechanical Engineering.

“It’s not just limited to these biomarkers or even diagnostic applications. It can sniff out industrial chemicals or airborne pollutants as well. If a molecule can form hydrogen bonds with water, we can use its vibrational fingerprint to detect it. It’s a pretty universal platform,” said Loza Tadesse, assistant professor of mechanical engineering at MIT, who is leading the project.

Related Links
MIT Department of Mechanical Engineering


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.